• 1-800-781-0477, 1-760-231-9471
  • Email:sales@AmericanPharmaWholesale.com
  • Site Map



Please email us at Sales@AmericanPharmaWholesale.com with our item No, NDC#,UPC#or best is product link. We are located in Oceanside, California. Search over 100,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name.
Menu

KALYDECO TB 150MG 60 CPLT

 Generic Name:
IVACAFTOR

 Description:
KALYDECO TB 150MG 60 CPLT DSHP 
 Alt Item #: 
4560538 related item: KALYDECO- ivacaftor granule 

 NDC:
51167-0200-02 Other ndcs: NDC Code(s): 51167-200-01, 511 Generic Name:
IVACAFTOR

 Description:
KALYDECO TB 150MG 60 CPLT DSHP 
 Alt Item #: 
4560538 related item: KALYDECO- ivacaftor granule 

 NDC:
51167-0200-02 Other ndcs: NDC Code(s): 51167-200-01, 511American Pharma Wholesale, Your Health Care Place.

KALYDECO TB 150MG 60 CPLT

$30723.60$28112.09

Item No.:RX351167-200025 Generic Name:
IVACAFTOR

Description:
KALYDECO TB 150MG 60 CPLT DSHP
Alt Item #:
4560538 related item: KALYDECO- ivacaftor granule

NDC:
51167-0200-02 Other ndcs: NDC Code(s): 51167-200-01, 51167-200-02, 51167-300-01, 51167-400-01
UPC:
351167-200025
Contract:

Contract Alias:

Strength:
150MG

Form:
TABLETS

Size:
1X60 EA Only Physician,Pharmacy or Licensed Facility can order this Rx Item NDC No.: 9716801,351167-200025,351167200025 UPC:351167200025,351167200

Have a question?

  Please email for current prices & Quanti

These highlights do not include all the information needed to use KALYDECO safely and effectively. See full prescribing information for KALYDECO. KALYDECO ® (ivacaftor) tablets, for oral use KALYDECO ® (ivacaftor) oral granules Initial U.S. Approval: 2012 RECENT MAJOR CHANGES Indications and Usage (1) 05/2017 INDICATIONS AND USAGE KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data. (12.1, 14) If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. (1) DOSAGE AND ADMINISTRATION Adults and pediatric patients age 6 years and older: one 150 mg tablet taken orally every 12 hours with fat-containing food. (2.2, 12.3) Pediatric patients 2 to less than 6 years of age and less than 14 kg: one 50 mg packet mixed with 1 teaspoon (5 mL) of soft food or liquid and administered orally every 12 hours with fat-containing food. (2.3, 12.3) Pediatric patients 2 to less than 6 years of age and 14 kg or greater: one 75 mg packet mixed with 1 teaspoon (5 mL) of soft food or liquid and administered orally every 12 hours with fat-containing food. (2.3, 12.3) Pediatric patients less than 2 years of age: not recommended. (2.4, 8.4) Reduce dose in patients with moderate and severe hepatic impairment. (2.5, 8.6, 12.3) Reduce dose when co-administered with drugs that are moderate or strong CYP3A inhibitors. (2.6, 7.1, 12.3) DOSAGE FORMS AND STRENGTHS Tablets: 150 mg (3) Oral granules: Unit-dose packets of 50 mg and 75 mg (3) CONTRAINDICATIONS None (4) WARNINGS AND PRECAUTIONS Elevated transaminases (ALT or AST): Transaminases (ALT and AST) should be assessed prior to initiating KALYDECO, every 3 months during the first year of treatment, and annually thereafter. In patients with a history of transaminase elevations, more frequent monitoring of liver function tests should be considered. Patients who develop increased transaminase levels should be closely monitored until the abnormalities resolve. Dosing should be interrupted in patients with ALT or AST of greater than 5 times the upper limit of normal (ULN). Following resolution of transaminase elevations, consider the benefits and risks of resuming KALYDECO dosing. (5.1, 6) Use with CYP3A inducers: Concomitant use with strong CYP3A inducers (e.g., rifampin, St. John's wort) substantially decreases exposure of ivacaftor, which may diminish effectiveness. Therefore, co-administration is not recommended. (5.2, 7.2, 12.3) Cataracts: Non-congenital lens opacities/cataracts have been reported in pediatric patients treated with KALYDECO. Baseline and follow-up examinations are recommended in pediatric patients initiating KALYDECO treatment. (5.3) ADVERSE REACTIONS The most common adverse drug reactions to KALYDECO (occurring in ?8% of patients with CF who have a G551D mutation in the CFTR gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Vertex Pharmaceuticals Incorporated at 1-877-634-8789 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS CYP3A inhibitors: Reduce KALYDECO dose to one tablet or one packet of granules twice a week when co-administered with strong CYP3A inhibitors (e.g., ketoconazole). Reduce KALYDECO dose to one tablet or one packet of granules once daily when co-administered with moderate CYP3A inhibitors (e.g., fluconazole). Avoid food containing grapefruit or Seville oranges. (7.1, 12.3) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 7/2017

 Generic Name:
IVACAFTOR

 Description:
KALYDECO TB 150MG 60 CPLT DSHP 
 Alt Item #: 
4560538 related item: KALYDECO- ivacaftor granule 

 NDC:
51167-0200-02 Other ndcs: NDC Code(s): 51167-200-01, 511
KALYDECO TB 150MG 60 CPLT
Generic Name: IVACAFTOR Description: KALYDECO TB 150MG 60 CPLT DSHP Alt Item #: 4560538 related item: KALYDECO- ivacaftor granule NDC: 51167-0200-02 Other ndcs: NDC Code(s): 51167-200-01, 511

 Generic Name:
IVACAFTOR

 Description:
KALYDECO TB 150MG 60 CPLT DSHP 
 Alt Item #: 
4560538 related item: KALYDECO- ivacaftor granule 

 NDC:
51167-0200-02 Other ndcs: NDC Code(s): 51167-200-01, 511
Vertex Pharma
Generic Name: IVACAFTOR Description: KALYDECO TB 150MG 60 CPLT DSHP Alt Item #: 4560538 related item: KALYDECO- ivacaftor granule NDC: 51167-0200-02 Other ndcs: NDC Code(s): 51167-200-01, 511

American Pharma Wholesale, Your Health Care Place.
American Pharma Wholesale
American Pharma Wholesale, Your Health Care Place.